Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 5, 2026
Compass Therapeutics, Inc. (CMPX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$14.9 million. As of Jun 30, 2026 it held $179.9 million in cash and investments and $9.6 million in total debt.
Revenue
$0
Net income
$-25.15M
-26.5% vs year-ago quarter
Operating cash flow
$-14.74M
-24.6% vs year-ago quarter
Free cash flow
$-14.91M
-26.0% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
180.09M
+30.2% vs year-ago quarter
Net cash
$170.25M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CMPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1738021
- Former names
- Olivia Ventures, Inc. (until Jun 8, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$27.0M | -$20.3M | -$18.0M | -$15.8M | -$21.1M |
| Net income | -$25.2M | -$18.3M | -$15.7M | -$14.3M | -$19.9M |
| Operating cash flow | -$14.7M | -$17.3M | -$13.3M | -$10.8M | -$11.8M |
| Free cash flow | -$14.9M | -$17.4M | -$13.3M | -$10.9M | -$11.8M |
| Total assets | $190.2M | $205.2M | $219.6M | $231.3M | $116.7M |
| Total liabilities | $24.1M | $18.7M | $22.8M | $21.6M | $23.5M |
| Stockholders' equity | $166.0M | $186.5M | $196.8M | $209.6M | $93.2M |
| Cash and investments | $179.9M | $194.7M | $208.9M | $219.9M | $100.9M |
| Total debt | $9.6M | $9.8M | $9.8M | $9.8M | $9.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 359 Compass Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.